JP2009541436A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009541436A5 JP2009541436A5 JP2009517173A JP2009517173A JP2009541436A5 JP 2009541436 A5 JP2009541436 A5 JP 2009541436A5 JP 2009517173 A JP2009517173 A JP 2009517173A JP 2009517173 A JP2009517173 A JP 2009517173A JP 2009541436 A5 JP2009541436 A5 JP 2009541436A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- disease
- cancer
- arthritis
- tetrahydrofuro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002193 Pain Diseases 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 230000001575 pathological effect Effects 0.000 claims 9
- 206010061218 Inflammation Diseases 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 206010003246 arthritis Diseases 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 230000004054 inflammatory process Effects 0.000 claims 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 7
- -1 6-Amino-2-methoxy-9H-purin-9yl Chemical group 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 208000008035 Back Pain Diseases 0.000 claims 5
- 201000005569 Gout Diseases 0.000 claims 5
- 201000008482 osteoarthritis Diseases 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 206010001513 AIDS related complex Diseases 0.000 claims 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims 4
- 208000036487 Arthropathies Diseases 0.000 claims 4
- 208000012659 Joint disease Diseases 0.000 claims 4
- 206010063837 Reperfusion injury Diseases 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 4
- 230000006378 damage Effects 0.000 claims 4
- 230000002939 deleterious effect Effects 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 230000009385 viral infection Effects 0.000 claims 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 3
- 102000007471 Adenosine A2A receptor Human genes 0.000 claims 3
- 108010085277 Adenosine A2A receptor Proteins 0.000 claims 3
- 206010002383 Angina Pectoris Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000035143 Bacterial infection Diseases 0.000 claims 3
- 206010006895 Cachexia Diseases 0.000 claims 3
- 208000001640 Fibromyalgia Diseases 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 208000004550 Postoperative Pain Diseases 0.000 claims 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 3
- 230000008484 agonism Effects 0.000 claims 3
- 206010003119 arrhythmia Diseases 0.000 claims 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 230000001363 autoimmune Effects 0.000 claims 3
- 230000001580 bacterial effect Effects 0.000 claims 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims 3
- 206010006451 bronchitis Diseases 0.000 claims 3
- 239000007795 chemical reaction product Substances 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- 230000000302 ischemic effect Effects 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 2
- 206010006811 Bursitis Diseases 0.000 claims 2
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010063094 Cerebral malaria Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 2
- 208000007514 Herpes zoster Diseases 0.000 claims 2
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000008930 Low Back Pain Diseases 0.000 claims 2
- 206010050219 Lumbar radiculopathy Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010027202 Meningitis bacterial Diseases 0.000 claims 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
- 208000000112 Myalgia Diseases 0.000 claims 2
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 claims 2
- 101100109871 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aro-8 gene Proteins 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 208000000450 Pelvic Pain Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 206010036105 Polyneuropathy Diseases 0.000 claims 2
- 206010065016 Post-traumatic pain Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 206010039203 Road traffic accident Diseases 0.000 claims 2
- 208000008765 Sciatica Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims 2
- 201000002661 Spondylitis Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000000491 Tendinopathy Diseases 0.000 claims 2
- 206010043255 Tendonitis Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010047163 Vasospasm Diseases 0.000 claims 2
- 208000026816 acute arthritis Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 201000009904 bacterial meningitis Diseases 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 208000019664 bone resorption disease Diseases 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 2
- 208000011379 keloid formation Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000013465 muscle pain Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 208000008423 pleurisy Diseases 0.000 claims 2
- 230000007824 polyneuropathy Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 231100000241 scar Toxicity 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 201000004415 tendinitis Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000000451 tissue damage Effects 0.000 claims 2
- 231100000827 tissue damage Toxicity 0.000 claims 2
- 230000009772 tissue formation Effects 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 206010000087 Abdominal pain upper Diseases 0.000 claims 1
- 208000000884 Airway Obstruction Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010061666 Autonomic neuropathy Diseases 0.000 claims 1
- 208000000003 Breakthrough pain Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000036004 Cow milk intolerance Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000007530 Essential hypertension Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010019027 Haemothorax Diseases 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- 208000035154 Hyperesthesia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102100020873 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000007914 Labor Pain Diseases 0.000 claims 1
- 208000035945 Labour pain Diseases 0.000 claims 1
- 201000008197 Laryngitis Diseases 0.000 claims 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010028116 Mucosal inflammation Diseases 0.000 claims 1
- 201000010927 Mucositis Diseases 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 206010049565 Muscle fatigue Diseases 0.000 claims 1
- 206010028735 Nasal congestion Diseases 0.000 claims 1
- 206010028836 Neck pain Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010061876 Obstruction Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 206010061339 Perineal pain Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 208000002151 Pleural effusion Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010038419 Renal colic Diseases 0.000 claims 1
- 206010038563 Reocclusion Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 201000010001 Silicosis Diseases 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 208000010513 Stupor Diseases 0.000 claims 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 1
- 206010071436 Systolic dysfunction Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000028911 Temporomandibular Joint disease Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- BFBWSTUFQBVHMI-IOSLPCCCSA-N [(3ar,4r,6r,6ar)-4-(6-amino-2-methoxypurin-9-yl)-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methanol Chemical compound C12=NC(OC)=NC(N)=C2N=CN1[C@H]1[C@@H]2OCO[C@@H]2[C@@H](CO)O1 BFBWSTUFQBVHMI-IOSLPCCCSA-N 0.000 claims 1
- MSFBMSSKQDPGII-XNIJJKJLSA-N [(3ar,4r,6r,6ar)-4-[6-amino-2-(2,5-difluorophenoxy)purin-9-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methanol Chemical compound N=1C=2N([C@H]3[C@@H]4OCO[C@@H]4[C@@H](CO)O3)C=NC=2C(N)=NC=1OC1=CC(F)=CC=C1F MSFBMSSKQDPGII-XNIJJKJLSA-N 0.000 claims 1
- KAEOWWXGTFDMEY-WGQQHEPDSA-N [(3ar,4r,6r,6ar)-4-[6-amino-2-[3-[4-(trifluoromethyl)phenyl]phenoxy]purin-9-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methanol Chemical compound N=1C=2N([C@H]3[C@@H]4OCO[C@@H]4[C@@H](CO)O3)C=NC=2C(N)=NC=1OC(C=1)=CC=CC=1C1=CC=C(C(F)(F)F)C=C1 KAEOWWXGTFDMEY-WGQQHEPDSA-N 0.000 claims 1
- BPTABBGLHGBJQR-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 BPTABBGLHGBJQR-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000024716 acute asthma Diseases 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims 1
- 229960003942 amphotericin b Drugs 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 208000023819 chronic asthma Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 238000011109 contamination Methods 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 210000004969 inflammatory cell Anatomy 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 210000004153 islets of langerhan Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000030175 lameness Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 208000008494 pericarditis Diseases 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 206010035653 pneumoconiosis Diseases 0.000 claims 1
- 201000003144 pneumothorax Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000005333 pulmonary edema Diseases 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 230000008695 pulmonary vasoconstriction Effects 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 239000002753 trypsin inhibitor Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 230000003966 vascular damage Effects 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 208000001319 vasomotor rhinitis Diseases 0.000 claims 1
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0601396 | 2006-06-27 | ||
| US83730806P | 2006-08-11 | 2006-08-11 | |
| PCT/EP2007/056375 WO2008000743A2 (en) | 2006-06-27 | 2007-06-26 | Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009541436A JP2009541436A (ja) | 2009-11-26 |
| JP2009541436A5 true JP2009541436A5 (enExample) | 2010-08-05 |
Family
ID=38545430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009517173A Pending JP2009541436A (ja) | 2006-06-27 | 2007-06-26 | 治療用化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7906518B2 (enExample) |
| EP (1) | EP2066685B1 (enExample) |
| JP (1) | JP2009541436A (enExample) |
| CN (1) | CN101479290A (enExample) |
| AT (1) | ATE500263T1 (enExample) |
| AU (1) | AU2007263726A1 (enExample) |
| BR (1) | BRPI0713901A2 (enExample) |
| CA (1) | CA2657973A1 (enExample) |
| DE (1) | DE602007012904D1 (enExample) |
| ES (1) | ES2361886T3 (enExample) |
| RU (1) | RU2009102512A (enExample) |
| WO (1) | WO2008000743A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110064671A1 (en) * | 2008-03-10 | 2011-03-17 | Cornell University | Modulation of blood brain barrier permeability |
| WO2010080540A1 (en) * | 2008-12-18 | 2010-07-15 | Inspire Pharmaceuticals, Inc. | Method for treating inflammatory conditions |
| RU2478391C2 (ru) * | 2011-05-20 | 2013-04-10 | Евгений Петрович Измайлов | Способ физиотерапевтического и консервативного лечения плеврита |
| RU2478392C2 (ru) * | 2011-05-20 | 2013-04-10 | Евгений Петрович Измайлов | Способ консервативного и физиотерапевтического лечения серозно-геморрагического плеврита |
| BR112015002249A2 (pt) * | 2012-08-01 | 2017-07-04 | Lewis And Clark Pharmaceuticals Inc | composto, um estereoisômero ou sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar um estado associado a receptor de adenosina a2a em um indivíduo; método para diagnosticar anormalidades de perfusão de miocárdio em um mamífero; e método para reduzir a pressão interocular em um indivíduo |
| US9822141B2 (en) | 2012-08-01 | 2017-11-21 | Lewis And Clark Pharmaceuticals, Inc. | N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists |
| US11541071B1 (en) * | 2021-12-16 | 2023-01-03 | Ascletis BioScience Co., Ltd | Nucleoside derivatives and methods of use thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968914A (en) | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| US5691188A (en) * | 1994-02-14 | 1997-11-25 | American Cyanamid Company | Transformed yeast cells expressing heterologous G-protein coupled receptor |
| ES2194320T3 (es) | 1997-06-03 | 2003-11-16 | Itochu Techno Chem Inc | Sustancias naturales antivirales o antitumorales y uso de las mismas. |
| US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| US6958324B2 (en) * | 1998-12-02 | 2005-10-25 | Inotek Pharmaceuticals Corporation | Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease |
| US6214807B1 (en) * | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
| US6894021B2 (en) * | 2000-02-17 | 2005-05-17 | Cv Therapeutics, Inc. | Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation |
| US6995148B2 (en) * | 2001-04-05 | 2006-02-07 | University Of Pittsburgh | Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy |
| US6713638B2 (en) * | 2001-05-18 | 2004-03-30 | Joel M. Linden | 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors |
| GB0114286D0 (en) * | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| GB0228723D0 (en) | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
| GB0305150D0 (en) | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Use of therapeutic compounds |
| GB0305149D0 (en) | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Compounds for the treatment of pain |
| EP1636230A4 (en) * | 2003-06-09 | 2010-06-16 | Endacea Inc | ADENOSINE A1 RECEPTOR ANTAGONISTS |
| CA2533402A1 (en) * | 2003-07-22 | 2005-02-03 | Cv Therapeutics, Inc. | A1 adenosine receptor antagonists |
| JP2007500689A (ja) * | 2003-07-31 | 2007-01-18 | サノフイ−アベンテイス | アミノキノリン誘導体およびアデノシンａ３リガンドとしてのそれらの使用 |
| US7504497B2 (en) * | 2003-10-21 | 2009-03-17 | Inspire Pharmaceuticals, Inc. | Orally bioavailable compounds and methods for inhibiting platelet aggregation |
| DE602004027409D1 (de) * | 2003-10-21 | 2010-07-08 | Inspire Pharmaceuticals Inc | Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation |
| JP2007509180A (ja) * | 2003-10-21 | 2007-04-12 | インスパイアー ファーマシューティカルズ，インコーポレイティド | 疼痛を治療するための、非ヌクレオチド組成物および方法 |
| KR20070004792A (ko) * | 2004-03-05 | 2007-01-09 | 캠브리지 바이오테크놀로지 리미티드 | 아데노신 수용체 작용제 |
| AU2005231440B9 (en) * | 2004-04-02 | 2012-02-23 | Dogwood Pharmaceuticals, Inc. | Selective antagonists of A2A adenosine receptors |
| JP2007536241A (ja) * | 2004-05-03 | 2007-12-13 | ユニバーシティ オブ バージニア パテント ファウンデーション | 糖尿病性腎症の処置のためのａ２ａアデノシンレセプターアゴニスト |
| EP1781101A2 (en) * | 2004-07-29 | 2007-05-09 | Metabasis Therapeutics, Inc. | Novel nucleoside derivatives |
| KR20070050484A (ko) * | 2004-09-09 | 2007-05-15 | 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Ａ1 및 ａ3 아데노신 수용체 아고니스트로서의 퓨린 유도체 |
| US8461128B2 (en) * | 2005-04-15 | 2013-06-11 | Sloan-Kettering Institute For Cancer Research | Anti-microbial agents and uses thereof |
| US7514417B2 (en) * | 2005-05-19 | 2009-04-07 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
| GB0514809D0 (en) * | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| DK1983990T3 (da) * | 2006-01-26 | 2011-07-11 | Us Gov Health & Human Serv | Allosteriske A3-adenosin-receptormodulatorer |
| US20080027022A1 (en) * | 2006-02-08 | 2008-01-31 | Linden Joel M | Method to treat gastric lesions |
| CA2644996A1 (en) * | 2006-03-02 | 2007-09-13 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
| CA2646333C (en) * | 2006-03-17 | 2014-06-17 | Cv Therapeutics, Inc. | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
| CA2655310A1 (en) * | 2006-06-22 | 2008-05-29 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists in the treatment of ischemia |
| EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
| US7691869B2 (en) * | 2007-03-30 | 2010-04-06 | King Pharmaceuticals Research And Development, Inc. | Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity |
| US20080312160A1 (en) * | 2007-04-09 | 2008-12-18 | Guerrant Richard L | Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist |
| US20080262001A1 (en) * | 2007-04-23 | 2008-10-23 | Adenosine Therapeutics, Llc | Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection |
| WO2009006046A1 (en) * | 2007-06-29 | 2009-01-08 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Dendrimer conjugates of agonists and antagonists of the gpcr superfamily |
| JP2011500716A (ja) * | 2007-10-16 | 2011-01-06 | ギリアード・パロ・アルト・インコーポレイテッド | Ａ３アデノシン受容体アンタゴニスト |
| WO2009061516A1 (en) * | 2007-11-08 | 2009-05-14 | New York University School Of Medicine | Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening |
| CN101938904A (zh) * | 2008-01-09 | 2011-01-05 | PGx健康有限责任公司 | 用a2ar激动剂鞘内治疗神经性疼痛 |
| CA2714516A1 (en) * | 2008-02-07 | 2009-08-13 | Gilead Palo Alto, Inc. | Abca-1 elevating compounds and the use thereof |
-
2007
- 2007-06-26 US US11/823,335 patent/US7906518B2/en not_active Expired - Fee Related
- 2007-06-26 DE DE602007012904T patent/DE602007012904D1/de active Active
- 2007-06-26 ES ES07765638T patent/ES2361886T3/es active Active
- 2007-06-26 AU AU2007263726A patent/AU2007263726A1/en not_active Abandoned
- 2007-06-26 AT AT07765638T patent/ATE500263T1/de not_active IP Right Cessation
- 2007-06-26 WO PCT/EP2007/056375 patent/WO2008000743A2/en not_active Ceased
- 2007-06-26 CA CA002657973A patent/CA2657973A1/en not_active Abandoned
- 2007-06-26 RU RU2009102512/04A patent/RU2009102512A/ru not_active Application Discontinuation
- 2007-06-26 BR BRPI0713901-2A patent/BRPI0713901A2/pt not_active IP Right Cessation
- 2007-06-26 JP JP2009517173A patent/JP2009541436A/ja active Pending
- 2007-06-26 CN CNA2007800246476A patent/CN101479290A/zh active Pending
- 2007-06-26 EP EP07765638A patent/EP2066685B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112694475B (zh) | 环烷基类和杂环烷基类抑制剂及其制备方法和应用 | |
| KR100781864B1 (ko) | 트리아졸로(4,5-ｄ)피리미딘 화합물의 신규 결정형 및비결정형 | |
| AU2016366541B2 (en) | Polycyclic compounds as inhibitors of Bruton's tyrosine kinase | |
| JP2007526291A5 (enExample) | ||
| IL297041A (en) | Inhibitors of human immunodeficiency virus replication | |
| EP2170838A1 (en) | Particulates of a crth2 antagonist | |
| RU2009102512A (ru) | Терапевтические соединения | |
| RU2004133811A (ru) | Новые соединения | |
| JP2009541438A5 (enExample) | ||
| RU2009102531A (ru) | Терапевтические соединения | |
| AU2010334804B2 (en) | Aminoalkylpyrimidine derivatives as histamine H4 receptor antagonists | |
| US12528782B2 (en) | Prodrugs in the modulation of interleukin | |
| SK14052003A3 (sk) | Použitie derivátov adenozínu na prípravu liečiva na liečenie syndrómu inzulínovej rezistencie a diabetu | |
| JP2009541437A5 (enExample) | ||
| RU2009102536A (ru) | Терапевтические соединения | |
| EP3212193A1 (en) | Crystalline forms of pemetrexed diacid and manufacturing processes therefor | |
| CN120457137A (zh) | N4-羟基胞苷的二酯衍生物及其用途 | |
| CN114149457B (zh) | 一种苯并[c][1,2]氧杂硼戊环-1(3H)-醇类合物及其用途 | |
| WO2012147104A1 (en) | Novel process for the preparation of etravirine | |
| JPH07165785A (ja) | ３′−フルオロピリミジンヌクレオシド類の製造方法 | |
| TW202543641A (zh) | Pde4b抑制劑的製備方法 | |
| KR20260014614A (ko) | P2x3 억제제의 제조 방법 및 중간체 | |
| CN115362160A (zh) | 用于制备1,2,4,6-四-o-乙酰基-3-叠氮基-3-脱氧-d-吡喃半乳糖苷的大规模方法 | |
| HK1144939B (en) | Particulates of a crth2 antagonist | |
| HK1181764A (zh) | Crth2拮抗劑的微粒 |